vs
Hayward Holdings, Inc.（HAYW）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Hayward Holdings, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$255.2M vs $207.3M），Hayward Holdings, Inc.净利率更高（9.2% vs -62.0%，领先71.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.5%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -5.3%）
海沃德控股前身为巴特利特-海沃德公司，是美国本土金属加工企业，总部位于马里兰州巴尔的摩，业务涵盖大型铸造、制造及工程建造板块。公司创立于19世纪30年代，1925年之前保持独立运营，1927年被科伯斯公司收购，之后长期作为其旗下事业部开展业务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
HAYW vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $255.2M | $207.3M |
| 净利润 | $23.4M | $-128.6M |
| 毛利率 | 46.5% | — |
| 营业利润率 | 16.6% | -54.7% |
| 净利率 | 9.2% | -62.0% |
| 营收同比 | 11.5% | 25.9% |
| 净利润同比 | 63.0% | 3.5% |
| 每股收益（稀释后） | $0.11 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $255.2M | — | ||
| Q4 25 | $349.4M | $207.3M | ||
| Q3 25 | $244.3M | $159.9M | ||
| Q2 25 | $299.6M | $166.5M | ||
| Q1 25 | $228.8M | $139.3M | ||
| Q4 24 | $327.1M | $164.6M | ||
| Q3 24 | $227.6M | $139.5M | ||
| Q2 24 | $284.4M | $147.0M |
| Q1 26 | $23.4M | — | ||
| Q4 25 | $68.4M | $-128.6M | ||
| Q3 25 | $24.0M | $-180.4M | ||
| Q2 25 | $44.8M | $-115.0M | ||
| Q1 25 | $14.3M | $-151.1M | ||
| Q4 24 | $54.7M | $-133.2M | ||
| Q3 24 | $16.5M | $-133.5M | ||
| Q2 24 | $37.6M | $-131.6M |
| Q1 26 | 46.5% | — | ||
| Q4 25 | 40.7% | — | ||
| Q3 25 | 51.2% | — | ||
| Q2 25 | 52.7% | — | ||
| Q1 25 | 49.5% | — | ||
| Q4 24 | 51.4% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 51.0% | — |
| Q1 26 | 16.6% | — | ||
| Q4 25 | 25.0% | -54.7% | ||
| Q3 25 | 16.8% | -106.9% | ||
| Q2 25 | 23.8% | -64.8% | ||
| Q1 25 | 14.6% | -102.6% | ||
| Q4 24 | 23.4% | -74.3% | ||
| Q3 24 | 14.7% | -94.6% | ||
| Q2 24 | 23.9% | -79.1% |
| Q1 26 | 9.2% | — | ||
| Q4 25 | 19.6% | -62.0% | ||
| Q3 25 | 9.8% | -112.8% | ||
| Q2 25 | 15.0% | -69.0% | ||
| Q1 25 | 6.3% | -108.5% | ||
| Q4 24 | 16.7% | -80.9% | ||
| Q3 24 | 7.3% | -95.7% | ||
| Q2 24 | 13.2% | -89.5% |
| Q1 26 | $0.11 | — | ||
| Q4 25 | $0.31 | $-1.28 | ||
| Q3 25 | $0.11 | $-1.81 | ||
| Q2 25 | $0.20 | $-1.17 | ||
| Q1 25 | $0.06 | $-1.57 | ||
| Q4 24 | $0.26 | $-1.34 | ||
| Q3 24 | $0.07 | $-1.40 | ||
| Q2 24 | $0.17 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $230.7M | $421.0M |
| 总债务越低越好 | $11.1M | — |
| 股东权益账面价值 | $1.6B | $-80.0M |
| 总资产 | $3.1B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
| Q1 26 | $230.7M | — | ||
| Q4 25 | $399.1M | $421.0M | ||
| Q3 25 | $448.3M | $202.5M | ||
| Q2 25 | $365.1M | $176.3M | ||
| Q1 25 | $181.3M | $127.1M | ||
| Q4 24 | $196.6M | $174.0M | ||
| Q3 24 | $274.2M | $150.6M | ||
| Q2 24 | $215.1M | $480.7M |
| Q1 26 | $11.1M | — | ||
| Q4 25 | $943.5M | — | ||
| Q3 25 | $947.7M | — | ||
| Q2 25 | $949.1M | — | ||
| Q1 25 | $950.4M | — | ||
| Q4 24 | $950.6M | — | ||
| Q3 24 | $959.9M | — | ||
| Q2 24 | $959.8M | — |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $-80.0M | ||
| Q3 25 | $1.5B | $9.2M | ||
| Q2 25 | $1.5B | $151.3M | ||
| Q1 25 | $1.4B | $144.2M | ||
| Q4 24 | $1.4B | $255.0M | ||
| Q3 24 | $1.4B | $346.8M | ||
| Q2 24 | $1.4B | $432.4M |
| Q1 26 | $3.1B | — | ||
| Q4 25 | $3.2B | $1.5B | ||
| Q3 25 | $3.0B | $1.2B | ||
| Q2 25 | $3.0B | $1.3B | ||
| Q1 25 | $3.0B | $1.3B | ||
| Q4 24 | $3.0B | $1.5B | ||
| Q3 24 | $2.9B | $1.5B | ||
| Q2 24 | $2.9B | $1.6B |
| Q1 26 | 0.01× | — | ||
| Q4 25 | 0.59× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.63× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.67× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-150.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | -6.45× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | $-150.6M | — | ||
| Q4 25 | $-26.9M | $-99.8M | ||
| Q3 25 | $94.6M | $-91.4M | ||
| Q2 25 | $194.2M | $-108.3M | ||
| Q1 25 | $-5.8M | $-166.5M | ||
| Q4 24 | $-63.7M | $-79.3M | ||
| Q3 24 | $65.9M | $-67.0M | ||
| Q2 24 | $287.0M | $-77.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-35.8M | $-100.8M | ||
| Q3 25 | $87.2M | $-92.7M | ||
| Q2 25 | $187.3M | $-110.7M | ||
| Q1 25 | $-11.4M | $-167.8M | ||
| Q4 24 | $-70.4M | $-79.5M | ||
| Q3 24 | $59.1M | $-68.6M | ||
| Q2 24 | $282.3M | $-79.0M |
| Q1 26 | — | — | ||
| Q4 25 | -10.3% | -48.6% | ||
| Q3 25 | 35.7% | -58.0% | ||
| Q2 25 | 62.5% | -66.5% | ||
| Q1 25 | -5.0% | -120.5% | ||
| Q4 24 | -21.5% | -48.3% | ||
| Q3 24 | 26.0% | -49.2% | ||
| Q2 24 | 99.3% | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 0.5% | ||
| Q3 25 | 3.0% | 0.8% | ||
| Q2 25 | 2.3% | 1.5% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 2.1% | 0.1% | ||
| Q3 24 | 3.0% | 1.2% | ||
| Q2 24 | 1.7% | 1.4% |
| Q1 26 | -6.45× | — | ||
| Q4 25 | -0.39× | — | ||
| Q3 25 | 3.94× | — | ||
| Q2 25 | 4.34× | — | ||
| Q1 25 | -0.41× | — | ||
| Q4 24 | -1.16× | — | ||
| Q3 24 | 4.00× | — | ||
| Q2 24 | 7.64× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAYW
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
